



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



MV1

Cat. No.:	HY-113534
CAS No.:	1001600-54-9
Molecular Formula:	C ₃₃ H ₄₄ N ₄ O ₅
Molecular Weight:	576.73
Target:	IAP; Apoptosis
Pathway:	Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (216.74 mM)

* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.7339 mL	8.6696 mL	17.3391 mL
	5 mM		0.3468 mL	1.7339 mL	3.4678 mL
	10 mM		0.1734 mL	0.8670 mL	1.7339 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

MV1 is an antagonist of IAP (inhibitor of apoptosis protein), leads to protein knockdown of HaloTag-fused proteins when combined with HaloTag ligand^[1].

In Vitro

MV1 (0.08-20 μM; 24 h) inhibits the growth of EVSAT cells^[1].
 MV1 (5 μM; 0-60 min) treatment causes rapid loss of c-IAP1 and c-IAP2 in MDA-MB-231 cells^[1].
 MV1 (5 μM; 1 h) treatment inducing degradation of c-IAP1 and c-IAP2 is dependent on proteasomal machinery but not on

caspase activation^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	EVSAT cells
Concentration:	0.08-20 μ M
Incubation Time:	24 hours
Result:	Showed IC ₅₀ value of 5 μ M for EVSAT cells.

Western Blot Analysis^[1]

Cell Line:	MDA-MB-231 cells
Concentration:	5 μ M
Incubation Time:	0-60 min
Result:	Showed the decrease of c-IAP1 and 2 protein levels by as early as two minutes following exposure.

REFERENCES

[1]. Eugene Varfolomeev, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81.

[2]. Tomoshige S, et al. Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand. Bioorg Med Chem. 2016 Jul 15;24(14):3144-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA